Browsing by Author "Priyamvada K. Gupta"

Now showing 1 - 5 of 5

Bioavailability enhancement of poorly soluble drugs with mesoporous silicon
(Elsevier, 2025) Saya Tyagi; Amrit Chattopadhaya; Priyamvada K. Gupta; Harshita Tiwari; Swati Singh; Ashish Verma; Vibhav Gautam
An emerging strategy to address solubility-related bioavailability issues is the formulation of weakly water-soluble medications utilizing ordered mesoporous silica materials. Because of their large surface areas and capacity to physically adsorb large drug loads in either molecular or amorphous form, mesoporous silica carriers enable molecular state drug release in aqueous gastrointestinal environments. They also have the potential to supersaturate, which promotes improved absorption and increased bioavailability. They are useful for creating drug delivery systems with steady and beneficial preclinical developments. Because of its unique physicochemical properties, including high porosity, large surface area, adjustable pore size and dimensions, good biocompatibility, and significant loading capacity, mesoporous silicon material effectively encapsulates, controls, and occasionally delivers biologic agents intracellularly for clinical use. This chapter provides an overview of the most recent developments in fabrication of mesoporous silicon, its potential for drug delivery, mechanism for increasing the bioavailability of poorly soluble drugs, the biocompatibility of mesoporous silicon both in vivo and in vitro, and their usage as diagnostic tools. It has been shown that silica may sustainably and precisely store and release medications, including antibiotics. Therefore the potential benefits of mesoporous silicon in drug transport can potentially be increased by its production and chemical modifications for biomedical applications. © 2026 Elsevier Inc. All rights reserved.
Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities
(John Wiley and Sons Inc, 2025) Harshita Tiwari; Swati Singh; Sonal Sharma; Priyamvada K. Gupta; Ashish Verma; Amrit Chattopadhaya; Brijesh Kumar; Sakshi Agarwal; Rajiv Kumar; Sanjeev Kumar Gupta; Vibhav Gautam
Triple negative breast cancer (TNBC) displays a notable challenge in clinical oncology due to its invasive nature which is attributed to the absence of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor (HER-2). The heterogenous tumor microenvironment (TME) of TNBC is composed of diverse constituents that intricately interact to evade immune response and facilitate cancer progression and metastasis. Based on molecular gene expression, TNBC is classified into four molecular subtypes: basal-like (BL1 and BL2), luminal androgen receptor (LAR), immunomodulatory (IM), and mesenchymal. TNBC is an aggressive histological variant with adverse prognosis and poor therapeutic response. The lack of response in most of the TNBC patients could be attributed to the heterogeneity of the disease, highlighting the need for more effective treatments and reliable prognostic biomarkers. Targeting certain signaling pathways and their components has emerged as a promising therapeutic strategy for improving patient outcomes. In this review, we have summarized the interactions among various components of the dynamic TME in TNBC and discussed the classification of its molecular subtypes. Moreover, the purpose of this review is to compile and provide an overview of the most recent data about recently discovered novel TNBC biomarkers and targeted therapeutics that have proven successful in treating metastatic TNBC. The emergence of novel therapeutic strategies such as chemoimmunotherapy, chimeric antigen receptor (CAR)-T cells-based immunotherapy, phytometabolites-mediated natural therapy, photodynamic and photothermal approaches have made a significant positive impact and have paved the way for more effective interventions. © 2024 Wiley Periodicals LLC.
Integration of Hyphenated Techniques for Characterizing and Chemical Profiling of Natural Products
(John Wiley and Sons Inc, 2025) Ashish Verma; Amrit Chattopadhaya; Priyamvada K. Gupta; Harshita Tiwari; Swati Singh; Lalit Kumar; Vibhav Gautam
The drug discovery from natural products has played an important role for therapeutic purposes, however, but in the past two decades, there has been a hurdle faced by researchers during purification and characterization. Traditional analytical approaches are insufficient to address the growing number of difficulties in natural product research. The hyphenated approach is a more advanced form that combines the benefits of separation with spectroscopy. The exceptional advancements in hyphenated systems have significantly expanded their applications in the investigation of natural products. The advancement of numerous chromatographic techniques such as HPLC, HPTLC, and GC, as well as spectroscopic techniques such as NMR, MS, FTIR, and UV, in addition to the advent of hyphenated techniques such as LC-MS, GC-MS, and LC-NMR, have significantly transformed the method of drug discovery from natural resources. This study discusses the general concepts and literature applications of productivity tools for natural product isolation and structural elucidation. These hyphenated methodologies will enhance the course of natural product research while reducing the time and cost invested in its investigation, hence speeding up the drug development process. © 2025 Wiley-VHCA AG, Zurich, Switzerland.
Phytosphingosine, a sphingolipid isolated from fungal endophyte Penicillium oxalicum, exerts cytotoxic effects against breast cancer cells and shows blood compatibility
(Nature Research, 2025) Ashish Verma; Swati Singh; Priyamvada K. Gupta; Harshita Tiwari; Lalit Kumar; Manoj Kumar Bharty; Vibhav Gautam
Plant-associated fungal endophytes hold great potential to synthesize metabolites similar to their host, with potential anticancer effects. The present study aims to identify lead compound in the ethyl acetate (EA) extract of fungal endophyte, Penicillium oxalicum, associated with a medicinal plant Amoora rohituka, responsible for the anti-breast cancer activity. The crude extract of P. oxalicum was subjected to High-performance liquid chromatography (HPLC) analysis and further, bioactivity-guided fractionation was performed for HPLC fractions based on cell viability assay. The potential fraction further showed dose-dependent generation of nitric oxide in breast cancer cells that indicates their activity in the induction of oxidative stress. The characterization of potential fraction was done using different analytical techniques, such as liquid chromatography coupled with quadrupole time of flight mass spectrometry (LC-Q-TOF-MS), high-resolution mass spectrometry (HRMS), Fourier transform-infrared (FTIR) spectroscopy, and both 1H and 13C nuclear magnetic resonance (NMR) spectroscopy that validates the mass, structure, and functional groups of the lead compound, identified as Phytosphingosine. Further, DAPI assay revealed Phytosphingosine induced alteration of nuclear morphology in breast cancer cells, indicating apoptotic events. The blood compatibility of Phytosphingosine was evidenced through hemolysis assay, thus suggesting its safety profile. This is the first report of the purification and characterization of Phytosphingosine from P. oxalicum, exhibiting anti-breast cancer activity. The cytotoxic potential of Phytosphingosine against MDA-MB-231 and MCF-7 cells suggests further exploration to elucidate its molecular cross-talks and signalling pathways to develop targeted therapy against BC. © The Author(s) 2025.
Urinary miRNAs in bladder cancer
(Elsevier B.V., 2025) Amrit Chattopadhaya; Sukhad Kural; Ashish Verma; Priyamvada K. Gupta; Harshita Tiwari; Swati Singh; Anuja Thakur; Rajiv Kumar; Satya Narayan Sankhwar; Santosh Kumar Singh; Sakshi Agarwal; Sanjana Mehrotra; Vibhav Gautam; Lalit Kumar
Urinary bladder cancer (UBC) is a prominent malignancy with high morbidity and mortality worldwide. Addressing this public health challenge requires the development of effective diagnostic and prognostic indicators. MicroRNAs (miRNAs) are short, non-coding sequences of nucleic acid that modulate gene expression. Due to their high stability in biofluids such as serum, blood and urine, they have become a viable source for non-invasive diagnosis of pathologic processes in general and UBC specifically. This review comprehensively explores the role of urinary miRNAs, both free and exosomal, in the diagnosis, progression, staging, grading, metastasis, recurrence, survival, and treatment of UBC that includes chemo and immunotherapy. Specific miRNAs such as miR-21, miR-126, miR-143, and miR-145 have shown potential as diagnostic markers, whereas others like miR-200 family, miR-34a, miR-125b, and miR-221 are valuable for prognostic and predictive assessment. The review also discusses mechanistic insights into miRNA function and addresses the challenges of translating these findings into clinical practice. It aims to bridge the knowledge gap between academicians, researchers, and medical practitioners by providing a platform to understand, exchange, research, and infer information that could lead to novel therapeutic strategies for UBC. Integration of urinary miRNAs into routine clinical practice could significantly enhance the management of UBC, offering a pathway to personalized medicine and improved patient outcomes, particularly in India, where UBC incidence is increasing. © 2024 Elsevier B.V.